Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 10,000 shares of the stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $17.28, for a total transaction of $172,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total transaction of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total transaction of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total transaction of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total transaction of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.02, for a total transaction of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total transaction of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.67, for a total transaction of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.76, for a total transaction of $1,156,051.68.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.06, for a total transaction of $304,762.50.

Shares of Crispr Therapeutics AG (NASDAQ CRSP) traded down $0.26 during trading hours on Friday, reaching $18.88. 272,599 shares of the company’s stock were exchanged, compared to its average volume of 282,198. Crispr Therapeutics AG has a 12-month low of $11.63 and a 12-month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same quarter in the prior year, the business earned ($2.77) EPS. Crispr Therapeutics’s revenue for the quarter was up 54.2% compared to the same quarter last year. sell-side analysts expect that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in CRSP. Allianz Asset Management GmbH purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $2,384,000. Granahan Investment Management Inc. MA lifted its holdings in shares of Crispr Therapeutics by 51.7% in the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after buying an additional 89,839 shares in the last quarter. Credit Suisse AG purchased a new stake in shares of Crispr Therapeutics in the first quarter worth about $1,742,000. Adams Street Partners LLC purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $1,019,000. Finally, Hershey Trust Co. purchased a new stake in shares of Crispr Therapeutics in the third quarter worth about $768,000. 24.55% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have weighed in on CRSP shares. Barclays reiterated a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a research report on Friday, September 8th. SunTrust Banks reiterated a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a research report on Friday, November 10th. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Chardan Capital reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, August 14th. Finally, BidaskClub lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $22.38.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/crispr-therapeutics-ag-crsp-major-shareholder-sells-172800-00-in-stock/1755902.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.